Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
- Status
- TERMINATED
- Phase
- PHASE2
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE2
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
- Status
- TERMINATED
- Phase
- PHASE2
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
- Status
- COMPLETED
- Phase
- PHASE1
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
- Status
- COMPLETED
- Phase
- PHASE2
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
- Status
- COMPLETED
- Phase
- PHASE1
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
- Status
- COMPLETED
- Phase
- PHASE3